PRECISION MEDICINE:

THE FUTURE OF MEDICAL CARE

8TH GLOBAL HEALTHCARE CONFERENCE

21 November 2016
Venue: Royal College of Physicians
lbs.pickevent.com/EN/HealthcareConference2016/

LBS Precision Medicine 2016 brochure_v4.indd 1 13/11/2016 20:59

 Welcome
W e would like to extend a warm
welcome to you on the occasion
of the 8th Global Healthcare Conference
hosted by the London Business School
Healthcare Club. As the healthcare industry
moves into the digital era, we are faced
with the opportunity of learning how to
use genetic information to create more
effective treatments and therapies that
treat individuals rather than just symptoms.
Find out why Precision Medicine, or
personalised medicine, is driving the future
of healthcare innovation.
We are excited to have Dr Jane Griffiths, Chairman
EMEA Janssen, to deliver the keynote speech. This will
be followed by two lively panel discussions on Delivering
Precision Medicine for Everyone and How Digital Technologies
are Enabling Precision Medicine and the Fireside Chat
about emerging themes of Precision Medicine including
implications of Precision Medicine in real world setting.
Finally, Dr Joanne Hackett will conclude the evening with her
keynote speech.
About the London
At this point, we would like to thank our sponsors, A.T. Business School
Healthcare Club
Kearny and The Boston Consulting Group and our strategic
partners, Johnson & Johnson and GSK. A special note of
gratitude to you, the participants, for your interest in the
conference and your continued support of the With over 3,000 student, alumni and staff members,
Healthcare Club. the London Business School Healthcare Club is one of
the largest and most active professional clubs
We believe we have assembled a truly stellar line-up of on campus.
speakers, panellists and moderators to make for a very lively
and informative evening. Our activities encompass all Life Sciences areas
including healthcare provision, biotechnology,
We hope you enjoy the evening! pharmaceuticals and medical technology.

Members of the Healthcare Club are active in a wide

range of sectors including entrepreneurship, industry,
consulting, banking, venture capital and private equity.

LBS Precision Medicine 2016 brochure_v4.indd 2 13/11/2016 20:59

 Agenda
5:00 – 6:00pm Registration and networking

6:00 – 6:10pm Welcome Speech

Andrew Likierman, Dean, London Business School

6:10 – 6:30pm Opening Keynote Speech

Jane Griffiths, Company Group Chairman,
Janssen EMEA

6:30 – 7:10pm Panel 1: Delivering Precision Medicine for Everyone

Chair – Nicos Savva
John Isaac, Mahiben Maruthappu, Jerry Cacciotti,
Blanca Rosales Saez

7:10 – 7:30pm Fireside Chat

Michael Thomas, Junaid Bajwa

7:30 – 8:00pm Networking and Dining Break

8:00 – 8:40pm Panel 2: How Digital Technologies are Enabling

Precision Medicine
Rabin Yaghoubi, Jackie Hunter, Roy Katso, Chris Meier

8:40 – 9:00pm Closing Remarks

 Joanne Hackett, Chief Commercial Officer,
Precision Medicine Catapult

9:00 – 10:00pm Networking Reception

LBS Precision Medicine 2016 brochure_v4.indd 3 13/11/2016 20:59

 About Precision Medicine

In January 2015, US president Barack Obama announced a

plan to invest $215m in “Precision Medicine Initiative”. Despite
traditional “one-size-fit-all” medicine designed for “average”
patients, Precision Medicine is a new concept in Healthcare
to segregate patients into subgroups based on their genetic
information, environment and lifestyles and to prevent diseases
/ design medical treatments based on differences among
subgroups. Precision Medicine is expected to bring innovations
in the world of Healthcare.

Traditional medicine Precision Medicine

SUBGROUP

One-size-fits-all Different
AVERAGE treatment
treatments SHIFT SUBGROUP
PATIENTS per subgroup

SUBGROUP

(profiles)
• genetic info
• environment
• lifestyle

The potential advantages of Precision Medicine can vary • Subdivision of medicine changes business models of
across areas, but some examples are: pharmaceutical companies from ‘blockbuster’ model to
• Higher effects of medical treatments ‘many-models-small-production’ model

• Medical treatments according to patients’ life plans
• Reduced medical expenses by better disease prevention
• Reduced side-effects
Also, the shift to Precision Medicine can have a huge impact
on each stakeholder in Healthcare industry. Therefore, it is
now indispensable for anyone surrounding this industry to
understand the trends in Precision Medicine and prepare for
the changes triggered by it.
• New entrants such as biopharma start-ups or IT
companies with capabilities in Big Data analysis and
Artificial intelligence increase roles in Healthcare industry
• The way local hospitals face patients
fundamentally changes
• Data security and privacy protections become a big issue
for governments
We hope you can get deeper insights through
this conference.

LBS Precision Medicine 2016 brochure_v4.indd 4 13/11/2016 20:59

 Welcome Speech &
Opening Keynote Speaker

SIR ANDREW LIKIERMAN

Professor Sir Andrew Likierman is
Dean of London Business School

Andrew was Founding Director of the Executive

MBA programme and has been a Professor at the
School for many years, lecturing on all the major
executive and degree programmes. His research
interests are in the field of the measurement of
performance and on the use of judgement
in management.
Andrew’s career has spanned work in the public and private He has also been a non-executive Director of the Bank of
sectors, as well as in professional life. Andrew has run a England, Barclays Bank Plc, and is a Past President of the
textile plant in Germany, been Head of the Government Chartered Institute of Management Accountants. He is
Accountancy Service and was a Managing Director of the currently a non-executive director of the quoted insurance
UK Treasury. Previous non-executive posts include Chairman underwriter Beazley plc and an Independent National
of the National Audit Office, of the Economists’ Bookshop Director of Times Newspapers. He was named by The
Group and of the market research firm MORI. Evening Standard as one of the 1000 most influential people
in London in 2015.

DR JANE GRIFFITHS
Company Group Chairman, Janssen EMEA2

Jane Griffiths is the first female Company

Group Chairman of Janssen in EMEA, the
pharmaceutical division of the Johnson & Johnson
family. She is responsible for this business across
the entire region.

Her personal approach focuses on sustainability,
accountability, openness and collaboration, and she is leading
Janssen EMEA to live these values. Jane has held a number
of senior sales, marketing and research & development
positions including International Vice President for Western
Europe and South Africa, and Head of Market Access for
Janssen EMEA.
She is a sponsor for the Women’s Leadership Initiative in
Janssen. Other industry roles include past Chairwoman
of the European Federation of Pharmaceutical Industries
and Associations (EFPIA) Executive Committee and
past Chairwoman of the Pharmaceutical Research and
Manufacturers of America (PhRMA) Europe Committee.
Jane is a sponsor of the Johnson & Johnson Global
Pharmaceuticals Sustainability Council. Jane is also Chair of
the Johnson & Johnson Corporate Citizenship Trust in EMEA
and a Board member.
Completing her PhD in Plant Biochemistry at the University
of Aberystwyth, UK in 1982, Jane Griffiths started her
Johnson & Johnson career as a sales representative.

LBS Precision Medicine 2016 brochure_v4.indd 5 13/11/2016 20:59

 Panel 1:
Delivering Precision
Medicine for everyone

One of the current challenges for Precision

Medicine is how to make it available for
everyone with affordable costs and methods.
In this panel, our experts provide a glimpse
into the exciting future in Precision Medicine
for everyone. How is the next generation of
sequencing or pharmacogenomics changing the
drug development approach? How well can the
UK health system afford and adapt to Precision
Medicine? What role does Precision Medicine
play in the transition from treating sickness to
preventing illness? What are the major challenges
ahead of us and how can they be tackled?
What are the top promising areas / fields?

Dr Nicos Savva, Moderator

Associate Professor, London Business School

Nicos Savva is an Associate Professor at the Management

Science and Operations Department of the LBS, where he
teaches courses on Data Analysis, Modelling and Healthcare
Management. Nicos’ research interests include hospital
operations and innovation / new product development.
His research has appeared in leading journals such as
Management Science, M&SOM, Production & Operations
Management and Nature Biotechnology. Nicos has acted as
a consultant to high-tech start-up companies, retail firms,
hospitals and a hedge fund. Besides LBS, Nicos has taught
at Columbia GSB, The Wharton School, and Cambridge
Judge Business School. Nicos holds a PhD in Management
Science, an MPhil in Finance and a BA in Physics, all from the
University of Cambridge.

LBS Precision Medicine 2016 brochure_v4.indd 6 13/11/2016 20:59

 Speakers

DR JOHN ISAAC DR MAHIBEN MARUTHAPPU

Senior Dr Neuroscience, Co-founder, NHS Innovation Accelerator
J&J Innovation Centre

John joined Johnson & Johnson in September 2016. In this Dr Mahiben Maruthappu is a London-based doctor and
role John uses his drug discovery and scientific experience to Co-founder of Revere Care, a technology company. He
identify and advance external opportunities in the areas of formerly advised the CEO of NHS England on over £100
Alzheimer’s Disease and Mood Disorders. billion of health spending, and established the NHS
Innovation Accelerator which benefitted 3 million people in 6
Prior to joining Johnson & Johnson, since November
months, signing 380 deals in its first year.
2014, John was Head of Neuroscience and Mental Health
at the Wellcome Trust. Previous to that he worked at Eli He has advised a range of organisations, from startups to
Lilly and Company at their neuroscience research campus multilaterals, including the Swiss government, the Experiment
near London, UK. At Lilly he led a team of labs dedicated Fund and the WHO. Maruthappu has a strong interest in
to identifying new therapies for Alzheimer’s disease and research with over 100 peer-reviewed publications and 50
schizophrenia. academic awards. His work has been featured by BBC News
and the international press.
John’s scientific interests centre on synaptic mechanisms in
circuit function, and how dysfunction causes psychiatric and He is Chairman of the UK Medical Students’ Association
neurological disease. John obtained a BSc in Pharmacology (UKMSA), and has authored three medical books.
and Biochemistry at the University of Southampton in Maruthappu was educated at Oxford, Cambridge and
1990 and remained at Southampton for his graduate work, Harvard universities; he was the first person from British
studying mechanisms of epilepsy with Prof Howard Wheal. healthcare to be included in Forbes’ 30 under 30, and
recently ranked amongst the 100 most influential leaders in
In 1994 he joined Dr Robert Malenka’s laboratory
health technology, globally.
at University of California San Francisco working on
mechanisms of long-term synaptic plasticity in hippocampus
and somatosensory cortex, also in close collaboration with
Dr Roger Nicoll. After completion of this post doc position,
John joined Prof Graham Collingridge’s laboratory at the
University of Bristol back in the UK in 1996, where he
completed a one year post doc before establishing his own
lab there. He rose up through the ranks to full Professor
before leaving in 2004 to set up a lab at the Intramural
Program at NINDS / NIH in Bethesda, MD, USA studying
mechanisms and roles of synaptic plasticity in developing
cortical circuits.

LBS Precision Medicine 2016 brochure_v4.indd 7 13/11/2016 20:59

 Speakers
JERRY CACCIOTTI
Partner, North America, A.T. Kearney
With over 20 years of consulting experience, Jerry focuses
on digital transformation, growth strategy, R&D and resource
allocation for life sciences clients. He is trusted advisor
across pharma, biotech, and consumer health sectors,
advising leaders on their most critical decisions –
to enter new sectors, diversify product offerings, or realign
commercial models for success in value-based markets.
Jerry has led major transformations of portfolio management
and R&D decision making processes for six of the top 12
global pharmas and he has written and spoken extensively on
the topic of portfolio strategy. In recent work, he developed
a patient-centered solution architecture (e.g., digital patient
& HCP engagement), to accelerate deployment of new
solution innovation for a mid-sized specialty pharma. Also,
for a leading digital health services company, he created
a strategy to enter patient-support services, defining a
36-month growth and M&A playbook helping clients align
scientific and commercial strategy with patient-centered,
value based markets. Jerry has broad experience across
disease categories, with particular depth in oncology and
immunology. He has worked across clinical, regulatory, and
commercial organizations and in most major geographies –
the U.S., major Europe, and primary emerging markets.
LBS Precision Medicine 2016 brochure_v4.indd 8
BLANCA ROSALES SAEZ
Executive Advisor – Business Development,
Molecular Health
Blanca Rosales Baez graduated in 1998 with honours from
a B.A. in International Trade from a top Latin-American
University in Mexico City and University of Massachusetts.
She then held various roles in different industries:
Competitive Intelligence in EPC for Oil & Gas; International
Tax Consultant with PricewaterhouseCoopers, Strategic
Advisor to the Presidency of Mexico.
Pursuant to this, she moved to London and in 2004
completed a full-time MBA at London Business School.
She graduated with specializations in Entrepreneurship,
Strategy and Analytical Marketing. During the MBA, Blanca
attained experience in the FMCG industry through a summer
internship, a shadowing and a 2nd -year project.
Upon graduation from the MBA, Blanca moved to
Switzerland where she served across various commercial
roles within Novartis’ global headquarters and later Novartis
UK country organization. These span across different
commercial functions in different parts of Pharma’s value
chain, as well as sundry therapeutic and disease areas.
In the latest years she became Head of New Products
Portfolio for Mundipharma (EU headquarters), and has now
ventured herself in transitioning her career towards the
entrepreneurial healthtech scene.
She’s now the Global Head of Business Development for
Pharma and Biotech within Molecular Health, based both
in Germany and the US East coast. Molecular Health is
a precision-medicine driven company that helps Pharma
interpret clinico-molecular data and apply innovative RWE
analytics to inform decisions that increase drug technical,
regulatory and commercial success. Blanca is passionate
about disruptive innovation, testing new business models
with new technologies, and children education.
13/11/2016 20:59
 Fireside Chat

A spirited discussion about emerging themes of

Precision Medicine including:
• Implications of Precision Medicine in real world settings
• Personalisation beyond the genome
• Top players that are expected to shape the landscape

MICHAEL THOMAS
Partner, Global

Michael Thomas is a Partner in A.T. Kearney’s Global

Pharmaceutical Practice.

He has consulted for over fifteen years in the pharmaceutical

industry, focusing on growth strategy and helping blue chip
clients to formulate strategic responses to changes in
the healthcare environment, working with senior
management teams.

His clients have included AstraZeneca, Bayer, EliLilly, Gilead, Other areas of consulting focus include: Organisational
GlaxoSmithKline, Johnson&Johnson, Novartis, Pfizer, Pliva design and performance management; Direct to Patient
/ Teva, Sanofi, Schering-Plough, Shire and Takeda and marketing; and Customer Relationship Management (CRM),
pharmaceutical industry associations in Europe and US. both as a business strategy and technology issue, and its
application to pharmaceutical sales and marketing. He has
His current area of interest is in examining the opportunities
advised a number of Top 10 players on their European and
that the pharmaceutical industry has to partner with
global strategies. He has contributed to many industry
healthcare providers to improve access and returns on
articles and is a frequent conference speaker.
innovation. Most recently he has advised and helped
innovation-based players assess the commercial and Before joining AT Kearney, Michael was EMEA leader for
organisational models required for success in the current Sales & Marketing in the pharmaceutical practices of IBM
market access environment. He has also advised companies and PwC Consulting. He has held a senior management
on how to support an ageing portfolio, particularly around position in Strategy and Planning with SmithklineBeecham,
more commercial approaches to channel management and before entering consultancy ran a PR agency specialising
to drive growth late in product lifecycles in the light of in lifestyle products.
increased generic competition. Michael is a leading expert on
value pricing in the pharmaceutical industry, helping clients
develop novel pricing and value approaches as low-cost
generics become the key comparator for new products.
More broadly he has helped the Industry in negotiations
with Government on issues relating to industrial strategy,
healthcare reform and pricing and re-imbursement.

LBS Precision Medicine 2016 brochure_v4.indd 9 13/11/2016 20:59

 Speakers Panel 2:
How digital
technologies are enabling
Precision Medicine

DR JUNAID BAJWA RABIN YAGHOUBI

Director of Healthcare Services, MSD Chief Commercial Officer, Babylon Health

Junaid Bajwa is a practicing GP in the NHS, and the Rabin is an accomplished digital executive. He was
Executive Director of Healthcare Services for MSD (UK). responsible for DoubleClick’s Media business globally,
ran Strategic Partnerships for Google in EMEA and
Junaid qualified as a GP in 2009 and has since gone on to
was President & COO of research engine FindTheBest,
undertake a number of roles within the NHS spanning the
where he ran strategy, operations, sales, marketing and
payer, provider, regulator and public health space. He has had
business development.
responsibilities in leading on Physical Health, Mental Health,
IT, & Integrated Care projects. In 2014, he was seconded
onto the NHS Leadership Academy Fast Track Executive
Programme, where he was appointed as the Redesign
Director of a large Integrated Mental Health & Community
Foundation Trust, and reviewed global health systems on
behalf of the NHS to drive quality improvement within the
Service. Thereafter, he was seconded to NHS England as a
Clinical Associate on the New Models of Care Programme.

In April 2015 he was appointed to his present MSD role

with the UK. The credo of the MSD Healthcare Services
group is to: support health systems to deliver the best level
of population health, all the while improving the patient
experience, and working to reduce the per capita cost of
healthcare spend. Since 2015, the Healthcare Services group
have led on setting up both internal and external partnerships
e.g. The NHS Testbeds Programme (NHS (national / local) /
with Verily (Google Life Sciences) / MSD), a partnership with
UCLP / BHRUT / MSD to develop a value based contract
for industry, and the group launched VelocityHealth (a
digital accelerator aiming to reimagine healthcare delivery, in
partnership with Telefonica).

Junaid lives in London with his wife and two young children,
and his hobbies include playing tennis, basketball and cricket.

10

LBS Precision Medicine 2016 brochure_v4.indd 10 13/11/2016 20:59

 DR JACKIE HUNTER
CEO, Benevolent Bio
(former Stratified Medical)
Jackie Hunter is the Chief Executive Officer of Benevolent
Bio. Benevolent Bio unites traditional pharmaceutical
development methodology with Artificial Intelligence to
augment the research capabilities of its drug scientists so
that they can gain new insights to increase the efficiency
of medicines development.
Jackie has over thirty years of experience in the
bioscience research sector, working across academia and
industry including leading neurology and gastrointestinal
drug discovery and early clinical development for
GlaxoSmithKline. She founded OI Pharma Partners in 2010
to support the life science sector in harnessing the power of
open innovation and most recently was Chief Executive of
the Biotechnology and Biological Sciences Research Council.
She holds a personal chair from St George’s Hospital Medical
School, which was awarded in recognition of her contribution
to bioscience research. In 2010 she was awarded a CBE
in the Queen’s Birthday Honours list for Services to the
Pharmaceutical Industry.
LBS Precision Medicine 2016 brochure_v4.indd 11
DR ROY KATSO
Director Open Innovation & Funding
Partnerships, GSK
Roy Katso’s responsibilities in the Bioelectronics R&D
Unit include identifying the best talent wherever it exits
in the world and building new ecosystems in partnership
with academics, technology companies, funding agencies
and philanthropic organisations in order to accelerate the
realisation of the delivery of the potential of Bioelectronic
Medicines. This is done through an Open Innovation ethos
and building partnerships that are multi-disciplinary in
nature, co-exist in a complementary manner, and share
a common vision of expediting delivering this treatment
modality to address unmet patient need. An example of this
is the Innovation Challenge where Roy isaccountable for
the identification and creation of global multi-disciplinary
teams to undertake the development of an open access
research platform with the ability to read, write and erase
the neuronal language in visceral organs of interest. Such
a common platform not only solves a major hurdle for
the bioelectronic medicine research community, but also
accelerates the technology development that may go into
future manifestations of therapeutic devices that will be at
the centre of new ventures and partnerships.
Previously, Roy received his Ph.D from Oxford University
as a Rosina Valerie-Howell Fellow, where he studied the
molecular mechanisms of an orphan receptor tyrosine-kinase
in ovarian cancer. He spent two years at the University
College London as a Ludwig Institute post-doctoral fellow,
where his research focussed on the role of PI-3 kinases in
cancer prior to joining GSK in 2001. Roy has worked for
GSK for 12 years where he has lead multi-disciplinary matrix
teams across a number of therapeutic areas and target
classes in the early discovery of medicines. Prior to joining
the Bioelectronics R&D Unit he worked in the R&D Strategy
where he was accountable for providing decision support and
program management for Pharmaceutical leadership
on a number of key projects.
11
13/11/2016 20:59
 Speakers
DR CHRIS MEIER
Principal, The Boston Consulting
Group, London
Chris Meier is a Principal in the London office of the Boston
Consulting Group, having joined BCG in 2012. Chris is a core
member of the firm’s Healthcare practice area, and is one of
the leaders of BCG’s scientist network.
Chris has worked intensively with clients in the pharma,
biotech, medtech, mainly in the US and Europe. He
has significant experience across pharmaceutical R&D,
innovation, operations and commercial.
In the digital space, Chris has supported many
pharmaceutical clients across a broad range of topics,
including digital development, data integration, and the
use of big data approaches in R&D. Chris has also helped
pharmaceutical companies develop precision medicine
strategies, including biomarker discovery and development,
and the integration of therapeutics with diagnostics.
Prior to joining BCG, Chris was Principal Scientist at UCB,
a biopharmaceutical company. In his industrial work he
contributed to the discovery of several drug candidates in
autoimmune diseases and oncology. Chris holds a PhD in
Biophysics from Oxford University, and an MBA from London
Business School (Class of 2012).
12
LBS Precision Medicine 2016 brochure_v4.indd 12
Closing Keynote Speaker
DR JOANNE HACKETT
Chief Commercial Officer,
Precision Medicine Catapult
Professor Joanne Hackett is the Chief Commercial Officer
at the Precision Medicine Catapult (PMC). She has been
actively involved in clinical research for over 15 years
in Canada, America, Germany, Sweden and the UK. An
accomplished entrepreneur, scientist and strategist, she has
experience in the execution and management of complex
business transactions, as well as broad business development
experience in negotiation, execution and management of
hundreds of transactions with pharma, biotech, academia
and non-profit organisations. Her expertise in creating
connections between industry, academia and the NHS will
help inform solutions the PMC are currently tackling and
support the growth of the UK Precision Medicine industry.
The PMC is innovating to build a world-leading, UK-based,
Precision Medicine industry. It is establishing this at pace
and scale so that it is safe, reliable and efficient in delivering
targeted treatments to meet patients’ personalised needs, at
an affordable cost. The PMC is headquartered in Cambridge,
with national and regional Centres of Excellence across the
UK. Working with companies, charities, academia, policy
makers, hospitals, patient groups and healthcare authorities
in these clusters and internationally, it will provide the
leadership to grow the industry while delivering local health
care impact.
13/11/2016 20:59
 Creating immediate
and growing advantage
A.T. Kearney is a leading global management consulting
firm with offices in more than 40 countries. Since 1926,
we have been trusted advisors to the world's foremost
organizations. A.T. Kearney is a partner-owned firm, committed
to helping clients achieve immediate impact and growing
advantage on their most mission-critical issues.

About A.T. Kearney’s Health Practice

The global health ecosystem is undergoing a tectonic shift: from youthful
to aging populations, from stable to evolving regulatory landscapes,
and from developed to developing markets. A.T. Kearney teams with
companies across biopharmaceuticals, medical devices, distributors
and pharmacies, payers and providers to address their strategic
and operational issues. Our experts bring a forward-thinking,
collaborative style that has proven to deliver immediate,
meaningful solutions that last.
www.atkearney.com

The HealthTech Challenge is a business idea competition created to

help students turn their HealthTech ideas into reality. Hosted by the
Healthcare Club of London Business School and the Deloitte Institute
of Innovation and Entrepreneurship at London Business School the
competition runs every year and offers mentorship, training, and the
Dhruv Batra Prize of £10,000 to the winning team. Deloitte Institute
of Innovation
The 2017 HealthTech Challenge opens beginning of February with the finals hosted and Entrepreneurship
by the London Business School Healthcare Club in mid-May. The challenge seeks
to encourage healthcare innovation across many different audiences and is open to
postgraduate students with scientific, engineering or business background.

Last year Innersight, an innovative start-up creating a 3D Visualization Technology for

Medical Imaging was the 2016 HealthTech Champion!

Key dates
• Kick-off event and Commencement of team registration beginning of February
• One or more physical mixer events will be also held to facilitate face-to-face
interaction between participants in mid-February
• First-round submission: March – end of March
• Announcement on finalists: mid-April
• Final presentation: May – end of May at London Business School

13

LBS Precision Medicine 2016 brochure_v4.indd 13 13/11/2016 20:59

 Our Sponsors

A.T. Kearney is a leading global management consulting firm with offices in more than 40
countries. At A.T. Kearney, we work together to provide every colleague with full and ready
access to the best of our firm to help you quickly achieve your full potential. We promise
immediate impact and growing advantage to our clients – and that same promise rings true
for our people. You will have an opportunity to contribute to client outcomes from day one.
Because we value collaboration, you will work with team members who will help you grow as
you help our clients solve their most mission-critical issues.

Our Strategic Partners

Conference Committee

fo

Helene Kadjar Sangeun Lee

MBA 2017 MBA 2017
Co-President Co-President

Josefina Haque Nick Gorsky Taku Edatsune Charlotte Hermans

MBA 2018 MBA 2018 MBA 2018 MBA 2018

14

LBS Precision Medicine 2016 brochure_v4.indd 14 13/11/2016 20:59

 Career opportunities as limitless as the lives you will touch….

Johnson & Johnson

Is pleased to sponsor the
2016 London Business School Healthcare
Conference
Calling all big thinkers and world-changers who want to drive their careers
forward across more than 275 leading businesses in Consumer, Pharmaceuticals
and medical devices... If you have the talent and desire to touch the world,
Johnson & Johnson has the career opportunities to help make it happen.

The world is waiting. Let’s get started.

www.jnj.com/careers @JNJUniversity

Johnson & Johnson Services, Inc. is a member of the Johnson & Johnson Family of Companies. © Johnson & Johnson Services, Inc. 2016. Johnson &
Johnson companies are equal opportunity employers

LBS Precision Medicine 2016 brochure_v4.indd 15 13/11/2016 20:59

 Today there are still millions of people without access to
basic healthcare, thousands of diseases without adequate
treatments and millions more people who suffer from
everyday ailments. At GSK we want to change this.

Who we are

We are on a mission to help people: do more, feel better,

live longer.
We are a science-led global healthcare company. We have three
world-leading businesses that research, develop and manufacture
innovative pharmaceutical medicines, vaccines and consumer healthcare
products.
We are committed to widening access to our products, so more people can
benefit, no matter where they live in the world or what they can afford to
pay.

How we do it
Transforming the way we work to better meet patient
needs
At GSK, we believe how we do business is as important as what we do – it’s
what makes us different - so we are challenging industry norms by
changing the way we work.

Why we do it
We know growing a sustainable business that develops innovative
pharmaceutical medicines, vaccines and consumer healthcare products is
critical to help us continue to tackle global healthcare challenges.

We have created a way of working that harnesses our scientific expertise, collaborative approach,
partnerships and global reach – to meet patient and consumer needs and deliver returns to our
shareholders.

To explore careers with purpose visit gsk.com/careers

LBS Precision Medicine 2016 brochure_v4.indd 16 13/11/2016 20:59